贝伐珠单抗辅助治疗非小细胞肺癌恶性胸腔积液的效果

Effect of Bevacizumab Adjuvant Therapy on Malignant Pleural Effusion in Non-small Cell Lung Cancer

目的:研究贝伐珠单抗辅助治疗非小细胞肺癌恶性胸腔积液的效果,以及对患者炎症因子及肿瘤标志物水平的影响。方法:选取2018年11月-2019年11月笔者所在医院收治的非小细胞肺癌合并恶性胸腔积液的患者65例为研究对象。按随机数字表法分为对照组和观察组,对照组33例,观察组32例。对照组通过静脉滴注顺铂及培美曲塞治疗,观察组在对照组的基础上予以静脉滴注贝伐珠单抗注射液治疗。观察两组患者治疗有效率,治疗前后肿瘤标志物水平、炎症水平及不良反应发生情况。结果:观察组治疗有效率90.62%,高于对照组的60.60%(P<0.05);治疗后观察组CEA、CA153、CYFRA21-1均低于对照组(P<0.05);治疗后观察组IL-2、IFN-γ高于对照组(P<0.05),IL-6低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗辅助治疗非小细胞肺癌恶性胸腔积液效果显著,可稳定肿瘤细胞,改善炎症,不增加不良反应。

Objective:To study the effect of Bevacizumab as adjuvant therapy on malignant pleural effusion in non-small cell lung cancer and its effect on the levels of inflammatory factors and tumor markers.Method:A total of 65 patients with non-small cell lung cancer and malignant pleural effusion treated in our hospital from November 2018 to November 2019 were selected as the study subjects.According to the random number table method,they were divided into the control group and the observation group,33 cases in the control group and 32 cases in the observation group.The control group was treated by intravenous drip of Cisplatin and Pemetrexed,and the observation group was treated by intravenous drip of Bevacizumab Injection on the basis of the control group.The effective rate of treatment,the level of tumor markers,the level of inflammation and the occurrence of adverse reactions before and after treatment were observed in both groups.Result:The effective rate of the observation group was 90.62%,which was higher than 60.60%of the control group(P<0.05).After treatment,CEA,CA153,CYFRA21-1 in the observation group were lower than those in the control group(P<0.05).After treatment,IL-2,IFN-γin the observation group were higher than those in the control group(P<0.05),and IL-6 was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bevacizumab is effective in the adjuvant treatment on malignant pleural effusion in non-small cell lung cancer,which can stabilize tumor cells,improve inflammation without increase adverse reactions.